Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501


A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal




This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Study Status: Completed


Condition Intervention Phase
Retraction of Colostomy Drug: Group 1 Standard of Care
Drug: Group 2 EXPAREL
Phase 4

Verified by Pacira Pharmaceuticals, Inc May, 2013

Sponsored by: Pacira Pharmaceuticals, Inc
Information provided by: Pacira Pharmaceuticals, Inc identifier: NCT01509638

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Cleveland Clinic Florida
Weston, Florida 33331
United States

Cleveland Clinic Ohio
Beachwood, Ohio 44122
United States

Marylise Boutros, M.D.., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site